GSK (LON:GSK) Posts Quarterly Earnings Results

GSK (LON:GSK) announced its quarterly earnings data on Wednesday. The company reported GBX 23.20 ($0.29) earnings per share for the quarter, Digital Look Earnings reports. GSK had a net margin of 12.83% and a return on equity of 33.30%.

GSK Stock Up 7.5 %

GSK stock traded up GBX 103.50 ($1.29) during trading on Wednesday, reaching GBX 1,483.50 ($18.52). The stock had a trading volume of 72,538,188 shares, compared to its average volume of 33,660,703. The company has a quick ratio of 0.73, a current ratio of 0.82 and a debt-to-equity ratio of 123.04. GSK has a 52-week low of GBX 1,282.50 ($16.01) and a 52-week high of GBX 1,823.50 ($22.76). The stock has a market cap of £60.53 billion, a PE ratio of 1,312.83, a P/E/G ratio of 1.24 and a beta of 0.31. The business has a 50 day moving average price of GBX 1,351.15 and a 200 day moving average price of GBX 1,457.70.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on GSK shares. JPMorgan Chase & Co. reissued an “underweight” rating on shares of GSK in a report on Tuesday, January 7th. Berenberg Bank dropped their price target on shares of GSK from GBX 1,820 ($22.72) to GBX 1,600 ($19.97) and set a “buy” rating on the stock in a research report on Friday, November 29th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. According to MarketBeat, GSK presently has an average rating of “Moderate Buy” and a consensus price target of GBX 1,805.83 ($22.54).

Insider Activity

In related news, insider Jonathan Symonds purchased 1,500 shares of the company’s stock in a transaction on Friday, December 20th. The shares were bought at an average cost of GBX 1,315 ($16.41) per share, for a total transaction of £19,725 ($24,619.32). Company insiders own 1.61% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.